Skip to main content
Log in

Topical treatment of postvitrectomy fibrin formation with tissue plasminogen activator

  • Published:
International Ophthalmology Aims and scope Submit manuscript

Abstract

Tissue plasminogen activator (tPA) is able to dissolve any fibrin material that forms in the anterior chamber or vitreous humor. This property has been reported by various experimental studies performed in rabbits.

The authors demonstrate the tPA eye drops administered to patients with postoperative hyphema, which did not respond to traditional therapy, gave rapid clearance of the clot.

Following its topical administration for the first time in patients, the harmless nature of the drug is emphasized as well as its efficacy. This study indicates the promising features of this drug which deserve further investigation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Crabbe SI, Cloninger CC. Tissue plasminogen activator: a new thrombolytic agent. Clin Pharm 1987; 6: 373–86.

    PubMed  Google Scholar 

  2. Howard GR, Vukich J, Fiscella RG, Farber MD, Goldberg MF. Intraocular tissue plasminogen activator in a rabbit model of traumatic hyphema. Arch Ophthalmol 1991; 109: 272–4.

    PubMed  Google Scholar 

  3. Jaffe JG, Hilel L, Han DP, Williams GA, Abrams GW. Treatment of postvitrectomy fibrin pupillary block with tissue plasminogen activator. Am J Ophthalmol 1989; 108: 170–5.

    PubMed  Google Scholar 

  4. Johnson MW, Olsen KR, Hernandez E, Irvine WD, Johnson RN. Retinal toxicity of recombinant tissue plasminogen activator in rabbit. Arch Ophthalmol 1990; 108:259–63.

    PubMed  Google Scholar 

  5. Johnson RN, Olsen K, Hernandez E. Tissue plasminogen activator treatment of postoperative intraocular fibrin. Ophthalmology 1988; 95: 592–5.

    PubMed  Google Scholar 

  6. Lambrou FH, Snyder RW, Williams GA, Lewandowski M. Treatment of experimental intravitreal fibrin with tissue plasminogen fibrin. Am Ophthalmol 1987; 104: 619–23.

    Google Scholar 

  7. Leet DM. Treatment of total hyphemas with urokinase. Am J Ophthalmol 1977; 84:79–84.

    PubMed  Google Scholar 

  8. Liebman SD, Pollen A, Podos SM. Treatment of experimental total hyphema with intraocular fibrinolytic agents. Arch Ophthalmol 1962; 68: 102–8.

    Google Scholar 

  9. Lim JI, Fiscella R, Tessler H, Gagliano DA, Alepuz VC, Mohler MA. Intraocular penetration of topical tissue plasminogen activator. Arch Ophthalmol 1991; 109:714–7.

    PubMed  Google Scholar 

  10. O'Rourke JF. An evaluation of intraocular streptokinase. Am J Ophthalmol 1955; 39: 119–36.

    PubMed  Google Scholar 

  11. Snyder RW, Lambrou FH, Williams GA. Intraocular fibrinolysis with recombinant human tissue plasminogen activator. Arch Ophthalmol 1987; 105: 1277–80.

    PubMed  Google Scholar 

  12. Williams GA, Lambrou FH, Jaffe GA, Snyder RW, Green GDJ, Devenyi RG, Abrams GW. Treatment of postvitrectomy fibrin formation with intraocular tissue plasminogen activator. Arch Ophthalmol 1988; 106:1055–8.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cellini, M., Baldi, A. & Possati, G.L. Topical treatment of postvitrectomy fibrin formation with tissue plasminogen activator. Int Ophthalmol 18, 351–353 (1994). https://doi.org/10.1007/BF00930313

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00930313

Key words

Navigation